Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck. (July 2016)

• Record Type: Journal Article
• Authors: Rosko, Andrew J.; Birkeland, Andrew C.; Wilson, Kevin F.; Muenz, Daniel G.; Bellile, Emily; Bradford, Carol R.; McHugh, Jonathan B.; Spector, Matthew E.
• Is Part Of: Otolaryngology--head and neck surgery. Volume 155:Number 1(2016:Jul.)
• Page Start: 106
• Page End: 112
• Publication Date: 2016-07
• Subjects: spindle cell -- sarcomatoid -- head and neck cancer -- biomarkers -- cMet -- cyclin D1 -- p16 -- EGFR; Head -- Surgery -- Periodicals; Neck -- Surgery -- Periodicals; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1177/0194599816636612
• Languages: English
• ISSNs: 0194-5998

Abstract

Objective: To determine biomarkers of recurrence and survival in patients with spindle cell variant squamous cell carcinoma (SpSCC) of the head and neck. Study Design: Retrospective case control study. Setting: Tertiary academic center. Subjects and Methods: Thirty-two SpSCC patients (mean age, 68.8) between 1987 and 2009 were identified and reviewed. A tissue microarray (TMA) was constructed from tumor specimens. Tumor biomarkers under study included p16, epidermal growth factor receptor (EGFR), p53, EZH2, cyclin D1, CD104, HGFa, p21, and cMET. An additional TMA was constructed from patients with non-SpSCC oral cavity squamous cell carcinoma for comparative purposes. The main outcomes were overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). Results: In the SpSCC cohort, tumors positive for cMet had worse OS ( P < .001). Patients positive for cMet ( P = .007), cyclin D1 ( P = .019), and p16 ( P = .004) had worse DSS. Recurrence-free survival was also worse in patients with tumors positive for cMet ( P = .037), cyclin D1 ( P = .012), and p16 ( P < .001). Compared with the oral cavity cohort, there was a significantly larger proportion of patients in the SpSCC group with tumors staining positive for cMet and a lower proportion of tumors positive for cyclin D1. Conclusion: cMet, cyclin D1, and p16 are predictive tumor biomarkers for risk of recurrence and worse DSS in patients with SpSCC.